Innovate UK awards AKLRD £675,000 for osteoarthritis drug
AKL Research and Development’s early-stage osteoarthritis drug has won a prestigious award from Innovate UK, as a potential “game-changing” treatment.
Read More
Tag: AKL Research and Development
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
